PUMA BIOTECHNOLOGY, INC. 8-K

What Happened

• Puma Biotechnology, Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held June 11, 2026 in Los Angeles. Stockholders elected all eight nominated directors for one-year terms. Broker non-votes totaled 6,064,713 across the director votes.
• The selection of KPMG LLP as the company’s independent registered public accounting firm for fiscal 2026 was ratified. The advisory vote on executive compensation (say-on-pay) was approved. A proposed amendment to extend the Auerbach Warrant (CEO Alan H. Auerbach’s warrant to buy 2,116,250 shares at $16.00) from October 4, 2026 to October 4, 2028 was not approved.

Key Details

• Director election totals (For / Withheld; broker non-votes = 6,064,713): examples — Alan H. Auerbach 37,130,678 / 785,624; Troy E. Wilson 32,546,955 / 5,369,347.
• Auditor ratification: KPMG LLP — For 42,612,940; Against 1,328,476; Abstain 39,599.
• Say-on-pay (advisory): For 29,326,673; Against 7,878,580; Abstain 711,049 (about 20.8% voted against among shares cast).
• Auerbach Warrant amendment: For 18,234,150; Against 19,596,238; Abstain 85,914 — the amendment failed (a majority voted against). The warrant covers 2,116,250 shares at $16.00 and was originally issued Oct 4, 2011 (amended June 15, 2021).

Why It Matters

• Board continuity: all nominated directors were re-elected, maintaining current leadership and governance through the next annual meeting.
• Auditor stability: ratifying KPMG keeps the same independent auditor for fiscal 2026, which investors often view as a continuity signal for financial reporting.
• Executive pay scrutiny: while say-on-pay passed, roughly one in five votes were against, indicating notable shareholder concern about executive compensation.
• Warrant outcome affects CEO equity/dilution: the rejection of the warrant extension means the Auerbach Warrant will expire under its current terms on Oct 4, 2026 unless the company and holder take further action approved by stockholders in the future.